444 related articles for article (PubMed ID: 36523992)
21. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
Liang X; Chen X; Li H; Li Y
Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
[TBL] [Abstract][Full Text] [Related]
22. First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis.
He M; Zheng T; Zhang X; Peng Y; Jiang X; Huang Y; Tan B; Yang Z
Cancer Immunol Immunother; 2022 Jun; 71(6):1345-1355. PubMed ID: 34657171
[TBL] [Abstract][Full Text] [Related]
23. Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis.
Zhao M; Shao T; Ren Y; Zhou C; Tang W
Front Pharmacol; 2022; 13():910656. PubMed ID: 36249794
[No Abstract] [Full Text] [Related]
24. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
[TBL] [Abstract][Full Text] [Related]
25. Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies.
Jiang M; Liu C; Ding D; Tian H; Yu C
Front Oncol; 2022; 12():827050. PubMed ID: 35619899
[TBL] [Abstract][Full Text] [Related]
26. Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis.
Liu J; Li C; Seery S; Yu J; Meng X
Oncoimmunology; 2020; 9(1):1746112. PubMed ID: 32313723
[TBL] [Abstract][Full Text] [Related]
27. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis.
Wang Z; Zhou F; Xu S; Wang K; Ding H
Cancer Med; 2023 Sep; 12(18):18516-18530. PubMed ID: 37584242
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.
Li ZC; Sun YT; Lai MY; Zhou YX; Qiu MZ
Int Immunopharmacol; 2022 Aug; 109():108790. PubMed ID: 35504202
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
31. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
32. Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
Freemantle N; Xu Y; Wilson FR; Guyot P; Chen CI; Keeping S; Konidaris G; Chan K; Kuznik A; Atsou K; Glowienka E; Pouliot JF; Gullo G; Rietschel P
Ther Adv Med Oncol; 2022; 14():17588359221105024. PubMed ID: 35747163
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
34. Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis.
Alifu M; Tao M; Chen X; Chen J; Tang K; Tang Y
Front Oncol; 2023; 13():1146905. PubMed ID: 37397392
[TBL] [Abstract][Full Text] [Related]
35. First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis.
Liu T; Ding S; Dang J; Wang H; Chen J; Li G
J Thorac Dis; 2019 Jul; 11(7):2899-2912. PubMed ID: 31463119
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials.
Li X; Yan S; Yang J; Wang Y; Lv C; Li S; Zhao J; Yang Y; Zhuo M; Wu N
Front Oncol; 2020; 10():574752. PubMed ID: 33585195
[TBL] [Abstract][Full Text] [Related]
37. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of different immunotherapies combined with chemotherapy as first-line therapy in patients with small cell lung cancer: a network meta-analysis.
Gong S; Li Q; Yu X; Yang S
Front Immunol; 2024; 15():1362537. PubMed ID: 38694505
[TBL] [Abstract][Full Text] [Related]
39. Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials.
Yin Q; Dai L; Sun R; Ke P; Liu L; Jiang B
Cancer Res Treat; 2022 Jul; 54(3):803-816. PubMed ID: 34696564
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Chen C; Tian P; Zhong J; Fan X
Front Oncol; 2023; 13():1151769. PubMed ID: 37152041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
